TSE:APS Aptose Biosciences (APS) Stock Price, News & Analysis → Next-Gen AI is Creating Millionaires Right Now (From InvestorPlace) (Ad) Free APS Stock Alerts C$1.00 -0.02 (-1.96%) (As of 03:13 PM ET) Add Compare Share Share Today's RangeC$1.00▼C$1.1250-Day RangeC$1.02▼C$1.7552-Week RangeC$1.00▼C$7.01Volume4,100 shsAverage Volume8,353 shsMarket CapitalizationC$16.31 millionP/E RatioN/ADividend Yield0.39%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades Get Aptose Biosciences alerts: Email Address Ad InvestorPlaceNext-Gen AI is Creating Millionaires Right NowI predict massive unemployment is coming. 800 million could lose their jobs, according to a McKinsey study, and 70% of all existing occupations could see a pay cut because of job elimination, according to Wired magazine.Here’s what I’m recommending now (includes 2 stock tickers). About Aptose Biosciences Stock (TSE:APS)Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More APS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APS Stock News HeadlinesMay 17, 2024 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc flat on Thursday (APS)May 17, 2024 | markets.businessinsider.comBuy Rating for Aptose Biosciences on Tuspetinib’s Promising AML Study and Synergistic PotentialJune 26, 2024 | InvestorPlace (Ad)Next-Gen AI is Creating Millionaires Right NowI predict massive unemployment is coming. 800 million could lose their jobs, according to a McKinsey study, and 70% of all existing occupations could see a pay cut because of job elimination, according to Wired magazine.May 15, 2024 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Reports Results for the First Quarter 2024May 14, 2024 | msn.comAPTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024May 14, 2024 | sfgate.comAptose Biosciences: Q1 Earnings SnapshotMay 14, 2024 | finance.yahoo.comAptose Biosciences Q1 Net Loss Falls, on Lower ExpensesMarch 28, 2024 | seekingalpha.comAptose Biosciences Inc. (APTO) Q4 2023 Earnings Call TranscriptJune 26, 2024 | InvestorPlace (Ad)Next-Gen AI is Creating Millionaires Right NowI predict massive unemployment is coming. 800 million could lose their jobs, according to a McKinsey study, and 70% of all existing occupations could see a pay cut because of job elimination, according to Wired magazine.March 25, 2024 | benzinga.comAptose Biosciences's Earnings: A PreviewJanuary 31, 2024 | finance.yahoo.comAptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment OptionDecember 20, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc flat on Wednesday (APS)December 9, 2023 | finance.yahoo.comAptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual MeetingNovember 30, 2023 | finance.yahoo.comAptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive RoleNovember 10, 2023 | finance.yahoo.comAptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comAptose Reports Results for the Third Quarter 2023November 2, 2023 | theglobeandmail.comAptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual MeetingNovember 2, 2023 | finance.yahoo.comAptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual MeetingOctober 30, 2023 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug TuspetinibOctober 26, 2023 | finance.yahoo.comAptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023October 20, 2023 | markets.businessinsider.comPromising Prospects of Tuspetinib Drive Buy Rating for Aptose Biosciences: An Analyst’s PerspectiveOctober 7, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc up on Friday (APS)August 25, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc up on Thursday (APS)August 22, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc flat on Monday (APS)August 11, 2023 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Reports Results for the Second Quarter 2023August 11, 2023 | finance.yahoo.comAptose Reports Results for the Second Quarter 2023August 7, 2023 | theglobeandmail.comAptose Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (APS)See More Headlines Receive APS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/26/2024Next Earnings (Estimated)8/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:APS CUSIPN/A CIKN/A Webaptose.com Phone+1-647-4799828FaxN/AEmployees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($10.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-51,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-293.95% Return on Assets-102.23% Debt Debt-to-Equity Ratio14.27 Current Ratio0.78 Quick Ratio5.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.63 per share Price / Cash Flow1.60 Book ValueC($0.37) per share Price / Book-2.70Miscellaneous Outstanding Shares16,310,000Free FloatN/AMarket CapC$16.31 million OptionableNot Optionable Beta1.47 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. William G. Rice Ph.D. (Age 59)Chairman, Pres & CEO Mr. Gregory K. Chow CPA (Age 45)MBA, BA, Sr. VP, CFO & Principal Accounting Officer Mr. Ernest Kitt B.S.M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell (Age 73)Chief Medical Officer Mr. Peter MurrayDirector of Clinical Devel.Key CompetitorsHelix BioPharmaTSE:HBPEmerald Health TherapeuticsCVE:EMHProMIS NeurosciencesTSE:PMNCovalon TechnologiesCVE:COVSmall PharmaCVE:DMTView All Competitors APS Stock Analysis - Frequently Asked Questions How have APS shares performed in 2024? Aptose Biosciences' stock was trading at C$3.35 at the start of the year. Since then, APS shares have decreased by 70.1% and is now trading at C$1.00. View the best growth stocks for 2024 here. When is Aptose Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our APS earnings forecast. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (TSE:APS) posted its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.14. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE), AltaGas (ALA), Aphria (APHA), Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD). How do I buy shares of Aptose Biosciences? Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:APS) was last updated on 6/26/2024 by MarketBeat.com Staff From Our PartnersLoophole for Biden’s New Digital Currency PlanHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming...Golden Crest | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredThe Hidden Anchor Investment of the Elite RevealedThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because sav...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.